EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals

John H Kimbrough iD, Joshua M Maher iD, Helio S Sader iD, Mariana Castanheira iD, Rodrigo E Mendes iD

Microbiology Spectrum · 05.11.2024 · 12 (11)

DOI: 10.1128/spectrum.01474-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 05.11.2024. Verfasst von John H Kimbrough und 4 weiteren Autor:innen. Beteiligte Einrichtung: JMI Laboratories/Element Iowa City, North Liberty, Iowa, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Pseudomonas aeruginosa, Microbial Sensitivity Tests, Acinetobacter. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shionogi (Shionogi & Co. Ltd.).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study reports the activity of cefiderocol against Enterobacterales, Pseudomonas aeruginosa , and Acinetobacter spp. isolates collected from the United States and Europe, including Israel and Turkey, from 2020 to 2021. Among Enterobacterales, 2.8% were carbapenem nonsusceptible (CNSE); cefiderocol inhibited 96.6%/85.1% [Clinical Laboratory Standards Institute (CLSI)/European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints] of these isolates. Imipenem-relebactam, meropenem-vaborbactam, and ceftazidime-avibactam displayed susceptibilities lower than cefiderocol against CNSE isolates (67.4–84.6% susceptible, CLSI). Cefiderocol was the only agent active against CNSE isolates carrying metallo-β-lactamase (MBL) carbapenemase or multiple carbapenemase genes (84.6%–92.3% susceptible, CLSI). Approximately 18% of carbapenem-susceptible Escherichia coli , Klebsiella pneumoniae , and Proteus mirabilis carried extended-spectrum-β-lactamases and/or plasmid-borne AmpC-encoding genes; cefiderocol inhibited 99.8%–100.0% (CLSI) of these genotypic groups. Multi-drug resistance (MDR) phenotypes were observed in 16.9% and 52.5% of P. aeruginosa and A. baumannii-calcoaceticus isolates, respectively. Carbapenemase genes were rare (4.9%) among cephalosporin and/or carbapenem nonsusceptible P. aeruginosa , compared to 87.6% carriage in A. baumannii-calcoaceticus , respectively. Against the MDR and carbapenemase-carrying P. aeruginosa and A. baumannii-calcoaceticus subsets, cefiderocol was active against 98.6%/98.7% and 97.1%/97.4% (CLSI), respectively. Only 69 isolates (0.3%) across all species groups were identified as cefiderocol nonsusceptible per CLSI criteria (>4 mg/L). Cefiderocol was the most active agent in vitro against Enterobacterales, P. aeruginosa, and Acinetobacter spp., with uniform activity against all phenotypic- and genotypic-resistant subsets. Coupled with the low incidence of nonsusceptibility observed across species groups, these results demonstrate cefiderocol as an important option for treating infections caused by pathogens with diverse mechanisms of resistance in US and European hospitals. IMPORTANCE The worldwide spread of multi-drug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacterales and Acinetobacter spp. poses a serious challenge in healthcare settings as infections caused by these organisms are commonly refractory to many frontline therapeutic agents. Multiple global health organizations highlighted these pathogens as critical priorities for new antibiotic development, thus necessitating continued surveillance of the activities of currently available antimicrobial agents and circulating mechanisms of resistance. To meet this need, this study phenotypically and genotypically characterized priority Gram-negative pathogens collected from patients in US and European hospitals to examine the activity of cefiderocol and other currently available treatment options, including carbapenems and β-lactam-β-lactamase inhibitor combinations. The results presented here provide a detailed perspective to healthcare practitioners of cefiderocol’s broad applicability, manifested in high activity and low nonsusceptibility rates, across phenotypic and genotypic organism groups relative to other agents and further support its use against the most intransigent infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsPseudomonas aeruginosaMicrobial Sensitivity TestsAcinetobacterCephalosporinsCefiderocolbeta-LactamasesUnited StatesEuropeHumansHospitalsBacterial ProteinsEnterobacteriaceaebeta-LactamsCarbapenemsDrug Resistance, Multiple, Bacterial

Stichwörter der Autor:innen

Acinetobacter baumanniiCREPseudomonas aeruginosacefiderocolmultidrug resistance

Substanzen

Anti-Bacterial AgentsCephalosporinsCefiderocolbeta-LactamasescarbapenemaseBacterial Proteinsbeta-LactamsCarbapenems

Autor:innen und Institutionen

  • JMI Laboratories/Element Iowa City, North Liberty, Iowa, USA.

ORCID-Profile: John H Kimbrough, Joshua M Maher, Helio S Sader, Mariana Castanheira, Rodrigo E Mendes

Förderung

  • Shionogi (Shionogi & Co. Ltd.)

Zitieren

APA

Kimbrough, J. H., Maher, J. M., Sader, H. S., Castanheira, M., & Mendes, R. E. (2024). In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals. Microbiology Spectrum, 12(11). https://doi.org/10.1128/spectrum.01474-24

Vancouver

Kimbrough JH, Maher JM, Sader HS, Castanheira M, Mendes RE. In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals. Microbiology Spectrum. 2024;12(11). doi:10.1128/spectrum.01474-24

BibTeX
@article{Kimbrough2024,
  author = {Kimbrough, John H and Maher, Joshua M and Sader, Helio S and Castanheira, Mariana and Mendes, Rodrigo E},
  title = {In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals},
  journal = {Microbiology Spectrum},
  year = {2024},
  volume = {12},
  number = {11},
  doi = {10.1128/spectrum.01474-24}
}
Kostenlos starten →